SCHEMBL21498209

SCHEMBL21498209

Cc1ccncc1-c1nc2c(o1)C(=O)c1ccccc1C2=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP1 O94782 6/20 0.64
USP8 P40818 4/20 0.64
OTUB1 Q96FW1 4/20 0.64
USP2 O75604 3/20 0.64
USP36 Q9P275 3/20 0.64
USP19 O94966 2/20 0.57
WDR48 Q8TAF3 1/20 0.57
UCHL3 P15374 1/20 0.52
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
CYP17A1 P05093 2/20 0.39
CYP1A2 P05177 2/20 0.39
IDO1 P14902 4/20 0.39
TDO2 P48775 1/20 0.38
F7 P08709 2/20 0.38
F3 P13726 2/20 0.38
F10 P00742 1/20 0.38
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7811858 0.86 USP1 (0.67) USP1USP8OTUB1USP2USP36
SCHEMBL19220486 0.80 USP1 (0.82) USP1USP8OTUB1USP2USP36
SCHEMBL21498206 0.79 USP1 (0.40) USP1USP8OTUB1USP2USP36
SCHEMBL29493043 0.78 USP1 (1.00) USP1USP8OTUB1USP2USP36
SCHEMBL19198053 0.78 USP1 (1.00) USP1USP8OTUB1USP2USP36
SCHEMBL19220488 0.75 USP1 (0.66) USP1USP8OTUB1USP2USP36
SCHEMBL7968066 0.74 USP1 (0.77) USP1USP8OTUB1USP2USP36
SCHEMBL7808123 0.74 USP1 (0.68) USP1USP8OTUB1USP2USP36
SCHEMBL7808221 0.74 USP1 (0.67) USP1USP8OTUB1USP2USP36
SCHEMBL29629183 0.73 USP1 (1.00) USP1USP8OTUB1USP2USP36

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450281-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450281-B1 Compounds and methods for treating cancer USP8, USP2, NEDD8 USP1 7/4885USP8 1/4885OTUB1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.